Berwyn, Pennsylvania (Business Wire) Virpax® Pharmaceuticals Inc. (“Virpax” or “Company”) (NASDAQ: VRPX), a company specializing in the development of pain management drug candidates, today announced the appointment of Gerald W. Bruce and Michael F. Dubin, certified public accountants on their board of directors.
“I am very pleased that our board of directors has added two knowledgeable professionals. Each of them has valuable experience and we look forward to their contribution, “commented Virpax President and CEO Anthony P. Mack.
About Gerald W. Bruce Gerald W. Bruce has been a company executive since August 2012. 2017 Vice President and Chief Operating Officer, has served in the pharmaceutical and medical nutrition industries for more than 30 years, including 20 years in senior leadership positions.
Mr. Bruce served as NitroMed’s Senior Vice President of Business Operations, responsible for formulating business strategies and leading the team responsible for the development and implementation of the first business plan for the treatment of heart failure products for start-ups. He worked in the medical nutrition industry for almost ten years as Vice President of Sales for Nutricia in Danone’s North American Department of Medical Nutrition. Ad-Center Alternative
Mr. Bruce began his career at Johnson & Johnson (NYSE: JNJ), where he held increasing leadership positions in sales and marketing responsibilities, eventually serving as a product manager for the Pain Relief Group. He then served as Vice President of Sales for Bristol-Myers Squibb (NYSE: BMY), leading the cardiovascular and metabolic sales team with sales of more than $ 1.2 billion. Since then, Mr. Bruce has served as Vice President of Managerial Marketing, leading the team responsible for formulating and implementing Bristol-Myers Squibb’s US $ 7 billion portfolio repayment strategy in the US.
Mr. Bruce received a bachelor’s degree in business administration from Lincoln University and a master’s degree in leadership from Georgetown University McDonough School of Business. He currently serves as President of the Board of Directors of the University of Lincoln and a member of the Executive Committee of the Board of Directors of the National Sales Network.
About Michael F. Dubin, CPA
Mike Dubin is a successful senior manager, CPA, independent consultant, consultant, and thought leader with 40 years in manufacturing, distribution, financial services, business and professional services, and pharmaceuticals. Experience and success, technology, retail and other industries. His areas of expertise and experience also include leading executive teams, executive leadership training, operations management, profit optimization, board governance, financial reporting, and other financial management matters. Prior to this, Mr. Du Bin served as managing partner and PA / SNJ office title at RSMUS LLP (RSM), a $ 2.8 billion professional services company with more than 12,000 employees. In 2010, he won RSM’s “National Achievement Award” and was shortlisted for the company’s “National Honesty Award.”
Mr. Dubin received a BA in economics (with honors) from the Wharton School of Business at the University of Pennsylvania. He served as a member of the RSM board of directors for four years. He was also a member of the board of directors and chair of the audit committee of a private company in Philadelphia that provides energy efficiency facilities and services, as well as a member of the board of directors and chair of the risk management committee of Pennsylvania Commercial Bank.
Mr. Dubin is professionally affiliated with PICPA and AICPA. He also served as an adjunct professor and course professor for two years at the Wharton School of Business, and was also visiting professor at the Wharton School of the University of Pennsylvania, Temple University, the University of Scranton, and Lehigh University. He has also served as an expert witness/consultant for the Federal Deposit Insurance Corporation (FDIC) and Resolution Trust Corporation (RTC).
About Virpax Pharmaceuticals
Virpax is developing branded non-addictive pain control product candidates, using its proprietary technology to optimize targeted drug delivery. Virpax initially used its three proprietary drug delivery platforms to seek FDA approval. Epoladerm ™ is a quantitative aerosol film formulation of topical diclofenac, which is being developed to control acute musculoskeletal pain and osteoarthritis.
Probudur ™ is a single-injection liposomal bupivacaine preparation that is being developed to control postoperative pain. Envelta ™ is an intranasal molecular envelope formulation of enkephalin, which is being developed to control acute and chronic pain, including cancer-related pain. Virpax also uses its intranasal molecular envelope (MET) technology to develop its candidate product PES200 to control post-traumatic stress disorder (PTSD) and its candidate product MMS019 to inhibit viral replication caused by influenza or SARS CoV2. For more information, please visit www.virpaxpharma.com.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the revised Private Securities Litigation Reform Act, including Those are related to our company. Planned clinical trials, product development, clinical and regulatory plans, market opportunities, competitive positions, possible or assumed future operating results, business strategies, potential growth opportunities, and other predictive statements. These forward-looking statements are based on current expectations, estimates, forecasts and forecasts of the industries and markets in which we operate, as well as management’s current beliefs and assumptions.
These statements can be identified through the use of forward-looking expressions, including, but not limited to, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, “potentials”, “forecasts” . “,” projects “,” “should”, “will” and similar and negative expressions of these terms. These statements are related to future events or our financial performance, involving known and unknown risks, uncertainties and other factors, including the potential to affect the recent COVID19 pandemic and ongoing social distancing efforts for the company’s operations, the clinical development plans and timing The potential impact of the table, which may cause actual results,
performance or achievements to be materially different from future results, performance or achievements or to be implied in forward-looking statements. These factors include those specified in the company’s filings with the US Securities and Exchange Commission Remind potential investors not to rely too heavily on these factors. h Forward-looking statements are only issued as of the date of this press release. The company does not assume any disclosure obligations